F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: Proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents

Experimental Hematology

Volumn 38, Issue 5, 2010, Pages 384-391

  Fox, Norma E ^a   Lim, Jihyang ^a   Chen, Rose ^a   Geddis, Amy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 5 TETRAZOLETHIOL; CYTOKINE RECEPTOR AGONIST; ERYTHROPOIETIN RECEPTOR; HYDROGEN; LGD 4665; M AMP4; RECOMBINANT THROMBOPOIETIN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; THROMBOPOIETIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CELL PROLIFERATION; CELL SURFACE; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; CONTROLLED STUDY; DRUG TARGETING; GENE MUTATION; HYDROGEN BOND; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR BINDING; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; THROMBOCYTOPENIA; WILD TYPE;

ANIMALS; CELL LINE; CELL MEMBRANE; HUMANS; HYDROGEN BONDING; INTERLEUKIN-3; LYMPHOCYTES; MICE; MUTAGENESIS, SITE-DIRECTED; PEPTIDES; PHOSPHORYLATION; POINT MUTATION; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 77951499323     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.02.007     Document Type: Article

References (20)

1. Ballmaier M., Germeshausen M., Schulze H., et al. c-Mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001, 97:139-146.
2. Ihara K., Ishii E., Eguchi M., et al. Identification of mutations in the c-Mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A 1999, 96:3132-3136.
3. King S., Germeshausen M., Strauss G., Welte K., Ballmaier M. Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. Br J Haematol 2005, 131:636-644.
4. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008, 371:395-403.
5. Bussel J.B., Kuter D.J., Pullarkat V., Lyons R.M., Guo M., Nichol J.L. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009, 113:2161-2171.
6. Bussel J.B., Provan D., Shamsi T., et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:641-648.
7. Dziewanowska ZE, Matsumoto RM, Zhang JK, et al. Single and multiple oral doses of LGD-4665, a small molecule thrombopoietin receptor agonist, increase platelet counts in healthy male subjects. Blood. ASH Annual Meeting Abstracts. 2007; 110:1298(Abstract).
8. Kuter D.J. New thrombopoietic growth factors. Blood 2007, 109:4607-4616.
9. Fox N.E., Chen R., Hitchcock I., Keates-Baleeiro J., Frangoul H., Geddis A.E. Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature. Exp Hematol 2009, 37:495-503.
10. Onishi M., Mui A.L., Morikawa Y., et al. Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer. Blood 1996, 88:1399-1406.
11. Drachman J.G., Kaushansky K. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci U S A 1997, 94:2350-2355.
12. Yang C., Li Y.C., Kuter D.J. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol 1999, 105:478-485.
13. Hitchcock I.S., Chen M.M., King J.R., Kaushansky K. YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood 2008, 112:2222-2231.
14. Syed R.S., Reid S.W., Li C., et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998, 395:511-516.
15. Middleton S.A., Johnson D.L., Jin R., et al. Identification of a critical ligand binding determinant of the human erythropoietin receptor. Evidence for common ligand binding motifs in the cytokine receptor family. J Biol Chem 1996, 271:14045-14054.
16. Barbone F.P., Middleton S.A., Johnson D.L., et al. Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships. J Biol Chem 1997, 272:4985-4992.
17. Germeshausen M., Ballmaier M., Welte K. MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Hum Mutat 2006, 27:296-301.
18. Inagaki K., Oda T., Naka Y., Shinkai H., Komatsu N., Iwamura H. Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities. Blood 2004, 104:58-64.
19. Sakai R., Nakamura T., Nishino T., et al. Xanthocillins as thrombopoietin mimetic small molecules. Bioorg Med Chem 2005, 13:6388-6393.
20. Krause S., Schmoldt H.U., Wentzel A., Ballmaier M., Friedrich K., Kolmar H. Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists. FEBS J 2007, 274:86-95.